Exportación Completada — 

Real‐World Outcomes of Patients with Metastatic Non‐Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

BACKGROUND. Evidence from cancer clinical trials has strong internal validity but can be difficult to generalize to real‐world patient populations. Here we analyzed real‐world outcomes of patients with metastatic non‐small cell lung cancer (mNSCLC) treated with programmed cell death protein 1 (PD‐1)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Khozin, Sean, Carson, Kenneth R., Zhi, Jizu, Tucker, Melisa, Lee, Shannon E., Light, David E., Curtis, Melissa D., Bralic, Marta, Kaganman, Irene, Gossai, Anala, Hofmeister, Philip, Torres, Aracelis Z., Miksad, Rebecca A., Blumenthal, Gideon Michael, Pazdur, Richard, Abernethy, Amy P.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Lung Cancer
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6516117/
https://ncbi.nlm.nih.gov/pubmed/30591549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0307
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares